CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 1st, 2022 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS EXCLUSIVE LICENSE AGREEMENT is made and entered into as of March, __ 2015 (the “Effective Date”), by and between Apogee Biotechnology Corp., a Pennsylvania corporation (“Apogee”) and RedHill Biopharma Ltd., an Israeli company (“RedHill”). Apogee and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
